Here are the 10-K annual reports from Adia Med Inc (ADIA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ADIA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADIA filings page.
ADIA Nutrition, Inc. filed its annual report, detailing a transition from a former shell into an operating regenerative-medicine and biologics business focused on stem-cell therapies and supplements. In 2025, the company generated $700,508 in revenue, mainly from sales of biologics and medical procedures, but recorded a net loss of $395,464 and an accumulated deficit of $15,973,482. Management’s auditors raised substantial doubt about ADIA’s ability to continue as a going concern. ADIA operates FDA-registered perinatal tissue products under Section 361, runs a Winter Park, Florida clinic, and uses a related-party credit line and small equity raises to fund operations while it scales its stem-cell and supplement activities.